This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Apr 2011

Financial Report: Bristol-Myers Squibb 1Q11

Bristol-Myers Squibb has posted net sales of $5.0bn for the first quarter ended 31 March 2011, an increase of 4%.

The New York drugmaker Bristol-Myers Squibb announced Thursday its financial results for the first quarter ended 31 March 2011.


U.S. sales were up 5% to $3.3 billion in the quarter. International sales increased 3% to $1.8 billion (1% excluding foreign exchange impact). Plavix sales were up 6% to $1.8 billion. Sustiva Franchise sales were $343 million (+2%). Baraclude sales were $275 million (+27%). Sprycel sales were up 31% to $172 million. Orencia sales were up 18% to $199 million. Abilify sales were $624 million (+1%). Reyataz sales were $366 million (-2%). R&D expenses increased 3% to $935 million in the quarter.


Related News